Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viltolarsen Extension Study in DMD
NCT03167255Phase 2Completed
- Sponsor
- NS Pharma, Inc.
- Start
- Jul 2017
- Primary completion
- Oct 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 2, open-label trial of viltolarsen in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by NS Pharma, Inc. Primary endpoints: Time to Stand at Week 205, Time to Stand Velocity at Week 205 and 1 more. Started Jul 2017; status: completed.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03167255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167255.